We have empirically developed gene-specific cognitive composite scores in MAPT, GRN and C9orf72 mutation carriers (GENFI-Cog) and demonstrated that that they provide feasible sample sizes for clinical trials to evaluate the effect of treatment on clinical progression from the prodromal to the fully symptomatic stage. Time-to-event analyses revealed that roughly 50% of the patients with a CDR® plus NACC FTLD of 0.5 progress to 1 or higher after a period of three years. The results from this study show that GENFI-Cog has potential as a cognitive endpoint in upcoming clinical trials and provide important guidelines on sample size recruitment and clinical trial duration.
The GENFI-Cog composites can be regarded as attractive clinical outcome measures because they produce substantially lower sample size estimates than most individual neuropsychological tests. Depending on the effect size (40–10%), sample size estimates ranged between 13–214 for C9orf72, 3–53 for GRN and 6–90 for MAPT per study arm for the weighted GENFI-Cog. A practical problem in trial design for FTD spectrum disorders is recruiting enough patients to test candidate therapeutics as FTD is ~ 200-fold less common than AD, with an estimated prevalence of 15/100,000 and approximately 10–20% of cases being caused by mutations in C9orf72, GRN and MAPT genes (4, 7, 41). It is therefore unlikely that a trial would be able to include many hundreds of patients per study arm, which our results show would be necessary for most individual neuropsychological tests. There were some individual neuropsychological tests that required reasonable sample sizes similar to that of GENFI-Cog, e.g. TMT and D-KEFS CWIT. These tests are typically included in clinical trials such as the current phase II study of AL001 (7). Yet, due to the heterogeneity in cognitive symptoms between individual patients even with the same genetic mutation, individually examining each cognitive test might not provide a sensitive and clinically meaningful primary outcome measure. Using GENFI-Cog will allow a single cognitive outcome to be used when analyzing treatment effect although validation in other large cohorts is warranted.
The CDR® plus NACC FTLD is currently often used as an inclusion criterion for clinical trials as well as for tracking disease progression. Results showed that roughly 50% of the patients with a CDR® plus NACC FTLD 0.5 progress to 1 or higher after a period of three years. This indicates that for trials with duration of three years around 50% of patients with CDR® plus NACC FTLD of 0.5 on entry to the trial would be expected to progress to CDR® plus NACC FTLD of 1 in the absence of effective disease modifying treatment. This means that if a treatment is expected to have a 20% effect the sample size corresponding to a 10% effect needs to be included per study arm to be able to demonstrate a treatment effect, because only half of the mutation carriers would be expected to progress from CDR® plus NACC FTLD 0.5 to 1 without treatment. This is important to consider when planning trial duration and recruitment with the current available clinical measures.
The optimal gene-specific cognitive composite score incorporated tests from different cognitive domains. For GRN mutation carriers, tests for executive function and social cognition contributed the most to the composite score, with the addition of tests for memory and language. In MAPT mutation carriers, there was a strong focus on semantic and episodic memory tests in the composite score with the addition of tests for attention and mental processing speed. A combination of tests from all cognitive domains was most sensitive in C9orf72 mutation carriers, with the strongest contribution from tests within the domains of executive function, social cognition and memory. These results complement recent studies showing cognitive decline in the early stages of FTD with widespread cognitive impairment covering multiple domains in C9orf72 (22, 42), dysexecutive functioning as the key feature in GRN (13, 22) and a specific impairment in episodic and semantic memory in MAPT-associated FTD (13, 20, 22). Impairment of social cognition appears to be a key feature in all three genetic groups (38), which was probably due to the high number of bvFTD cases in the sample. Neuroimaging studies have indeed shown that the neurodegenerative process in C9orf72 mutation carriers typically is reflected by widespread degeneration in frontal, temporal as well as cerebellar and subcortical structures (42), whereas focal atrophy of the anteromedial temporal lobe, an area important for memory and semantic functioning, is often seen in MAPT-associated FTD (43). In GRN mutation carriers the typical pattern of degeneration includes the inferior frontal regions as well as the cingulate cortex, areas known to be critical in executive function (43). Thus, although the GENFI-Cog was empirically derived, the selected tests are clinically meaningful and in line with a theoretically driven approach where the composite would be constructed a priori from cognitive tests that are known to decline in the early stages of each genetic group.
This is to our knowledge the first study that has created cognitive composites for genetic forms of FTD by selecting the most sensitive combinations of cognitive variables based on systematic comparisons with controls. A major strength of this study is the use of a large cohort of genetic FTD mutation carriers allowing gene-specific analyses, but also the use of a matched control group of mutation negative family members. Another strength is the use of LASSO with cross-validation to avoid overfitting bias to ensure that results have generalizability (40).